摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-{(E)-3-[1-(3,5-dimethylisoxazol-4-ylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]acryloyl}-3,4-difluorobenzenesulfonamide | 882998-72-3

中文名称
——
中文别名
——
英文名称
N-{(E)-3-[1-(3,5-dimethylisoxazol-4-ylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]acryloyl}-3,4-difluorobenzenesulfonamide
英文别名
(E)-N-(3,4-difluorophenyl)sulfonyl-3-[1-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-5-fluoro-3-methylindol-7-yl]prop-2-enamide
N-{(E)-3-[1-(3,5-dimethylisoxazol-4-ylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]acryloyl}-3,4-difluorobenzenesulfonamide化学式
CAS
882998-72-3
化学式
C24H20F3N3O4S
mdl
——
分子量
503.502
InChiKey
ZERUZZSPUFDMCH-QPJJXVBHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    35
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    103
  • 氢给体数:
    1
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-(bromomethyl)-3,5-dimethylisoxazole3,4-difluoro-N-[(E)-3-(5-fluoro-3-methyl-1H-indol-7-yl)acryloyl]benzenesulfonamidepotassium tert-butylate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以31%的产率得到N-{(E)-3-[1-(3,5-dimethylisoxazol-4-ylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]acryloyl}-3,4-difluorobenzenesulfonamide
    参考文献:
    名称:
    Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding
    摘要:
    The EP(3) receptor on the platelet mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP(3) receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged oil a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.
    DOI:
    10.1021/jm9005912
点击查看最新优质反应信息

文献信息

  • Structure−Activity Relationship Studies Leading to the Identification of (2<i>E</i>)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-l<i>H</i>-indol-7-yl]-<i>N</i>-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding
    作者:Jasbir Singh、Wayne Zeller、Nian Zhou、Georgeta Hategan、Rama K. Mishra、Alex Polozov、Peng Yu、Emmanuel Onua、Jun Zhang、José L. Ramírez、Gudmundur Sigthorsson、Margret Thorsteinnsdottir、Alex. S. Kiselyov、David E. Zembower、Thorkell Andrésson、Mark E. Gurney
    DOI:10.1021/jm9005912
    日期:2010.1.14
    The EP(3) receptor on the platelet mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP(3) receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged oil a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.
查看更多